-
Recent Posts
Recent Comments
Archives
- October 2012
- December 2011
- November 2011
- September 2011
- March 2011
- December 2010
- November 2010
- September 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- November 2009
- October 2009
- September 2009
- July 2009
- June 2009
- February 2009
- January 2009
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- February 2007
- December 2006
- November 2006
- October 2006
- August 2006
- April 2006
- March 2006
- December 2005
- November 2005
- July 2005
- March 2005
- February 2005
- January 2005
- December 2004
- November 2004
- October 2004
- September 2004
- August 2004
Categories
Meta
Monthly Archives: July 2007
Acomplia (rimonabant) and depression
The European Medicines Agency (EMEA) is recommending that rimonabant (indication: obesity) should not be used in those with major depression or those taking anti-depressants because of a risk of psychiatric side effects. Advice for patients taking rimonabant: If you are … Continue reading
Oseltamivir (Tamiflu) and causality
The Japan Institute of Pharmacovigilance has written to the BMJ concerning a editorial concerning oseltamivir. The letter states the following: On 16 June 2007 the Japanese Ministry of Health Labour and Welfare announced that by 31 May 2007 it had … Continue reading
Posted in ADRs, Spontaneous reporting
Comments Off
HRT and cardiovascular risk
The BMJ has published the WISDOM Trial of HRT in postmenopausal women aged 50 to 69 years-of-age (mean age 62.8 SD 4.8). Key points: Combined hormone therapy (n=2196) was compared with placebo (n=2189): significant increase in the number of major … Continue reading
Posted in ADRs, Patient Safety
Comments Off